<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0509234135
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LOVRAK 250MG POWDER FOR I.V. INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ACYCLOVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        21.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Lovrak</strong> contains a medicine called Acyclovir. This belongs to a group of medicines called antivirals. It works by killing or stopping the growth of viruses.</p><p><strong>Lovrak can be used to:</strong></p><p>&bull; Treat chickenpox</p><p>&bull; Treat severe cases of genital herpes</p><p>&bull; Treat and stop cold sores and genital herpes in people whose immune systems &nbsp;work less well, which means their bodies are less able to fight infections</p><p>&bull; Treat serious virus infections in children up to 3 months of age. This can rarely be caused by the virus responsible for cold sore infection and genital herpes.</p><p>&bull; Treat inflammation of the brain. This can rarely be caused by the virus responsible for cold sore infection and genital herpes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not have Lovrak:</strong></p><p>&bull; If you are allergic to Acyclovir or valAcyclovir or any of the other ingredients of this medicine (listed in Section 6).</p><p>Do not take <strong>Lovrak </strong>if the above applies to you. If you are not sure, talk to your doctor or pharmacist before having <strong>Lovrak</strong>.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before having<strong> Lovrak</strong> if:</p><p>&bull; You have kidney problems</p><p>&bull; You are over 65 years of age.</p><p>If you are not sure if the above apply to you, talk to your doctor or pharmacist before taking <strong>Lovrak</strong>.</p><p>It is important that you drink plenty of water while taking <strong>Lovrak</strong></p><p><strong>Other medicines and Lovrak</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>This includes medicines obtained without a prescription, including herbal medicines.</p><p>In particular tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&bull; &nbsp;Probenecid, used to treat gout</p><p>&bull; &nbsp;Cimetidine, used to treat stomach ulcers</p><p>&bull; Tacrolimus, ciclosporin or mycophenolate mofetil, used to stop your body rejecting transplanted organs.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Lovrak contains sodium</strong></p><p><strong>Lovrak</strong> contains sodium. To be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How your medicine is given</strong></p><p>You will never be expected to give yourself this medicine. It will always be given to you by a person who is trained to do so.</p><p>Before the medicine is given to you it will be diluted.</p><p><strong>Lovrak</strong> will be given to you as a continuous infusion into your vein. This is where the drug is slowly given to you over a period of time.</p><p>The dose you will be given, the frequency and the duration of the dose will depend on:</p><p>&bull; the type of infection you have</p><p>&bull; your weight</p><p>&bull; your age.</p><p><strong>Your doctor may adjust the dose of Lovrak if:</strong></p><p>&bull; You have kidney problems. If you have kidney problems, it is important you receive plenty of fluids while you are being treated with<strong> Lovrak</strong>.</p><p>Talk to your doctor before having<strong> Lovrak</strong> if any of the above apply.</p><p><strong>If you are given too much Lovrak</strong></p><p>If you think you have been given too much <strong>Lovrak</strong>, talk to your doctor or nurse straight away.</p><p>If you have been given too much <strong>Lovrak </strong>you may:</p><p>&bull; Feel confused or agitated</p><p>&bull; Have hallucinations (seeing or hearing things that aren&rsquo;t there)</p><p>&bull; Have fits</p><p>&bull; Become unconscious (coma).</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 1.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p><strong>Allergic reactions (may affect up to 1 in 10,000 people)</strong></p><p>If you have an allergic reaction<strong>, stop taking Lovrak and see a doctor straight away</strong>. The signs may include:</p><p>&bull; Rash, itching or hives on your skin</p><p>&bull; Swelling of your face, lips, tongue or other parts of your body</p><p>&bull; Shortness of breath, wheezing or trouble breathing</p><p>&bull; Unexplained fever (high temperature) and feeling faint, especially when standing up.</p><p><strong>Other side effects include:</strong></p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><p>&bull; Feeling or being sick</p><p>&bull; Itchy, hive-like rash</p><p>&bull; Skin reaction after exposure to light (photosensitivity)</p><p>&bull; Itching</p><p>&bull; Swelling, redness and tenderness at the site of injection.</p><p>&bull; Increase in the liver enzymes.</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><p>&bull; Reduced numbers of red blood cells (anaemia)</p><p>&bull; Reduced numbers of white blood cells (leukopenia)</p><p>&bull;Reduced numbers of blood platelets (cells that help the blood to clot) (thrombocytopenia).</p><p><strong>Very rare</strong> (may affect up to 1 in 10,000 people)</p><p>&bull; Headache or feeling dizzy</p><p>&bull; Diarrhoea or stomach pains</p><p>&bull; Feeling tired</p><p>&bull; Fever</p><p>&bull; Effects on some blood urine tests</p><p>&bull; Feeling weak</p><p>&bull; Feeling agitated or confused</p><p>&bull; Shaking or tremors</p><p>&bull; Hallucinations (seeing or hearing things that aren&rsquo;t there)</p><p>&bull; Fits</p><p>&bull; Feeling unusually sleepy or drowsy</p><p>&bull; Unsteadiness when walking and lack of coordination</p><p>&bull; Difficulty speaking</p><p>&bull; Inability to think or judge clearly</p><p>&bull; Unconsciousness (coma)</p><p>&bull; Paralysis of part or all of your body</p><p>&bull; Disturbances of behaviour, speech and eye movements</p><p>&bull; Stiff neck and sensitivity to light</p><p>&bull; Inflammation of the liver (hepatitis)</p><p>&bull; Yellowing of your skin and whites of your eyes (jaundice)</p><p>&bull; Kidney problems where you pass little or no urine</p><p>&bull; Pain in your lower back, the kidney area of your back or just above your hip (renal pain).</p><p>&nbsp;</p><p><strong>If you get any side effects, tell your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. </strong></p><p><strong><u>To report any side effect(s): </u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222,</p><p><strong>Exts:</strong> 2317-2356-2353-2354-2334-2340.</p><p><strong>Toll free phone:</strong> 8002490000</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp; Do not use <strong>Lovrak </strong>after the expiry date which is stated on the carton and the inner label.</p><p>-&nbsp; Store below 30<sup>o</sup>C.</p><p>-&nbsp; Do not use <strong>Lovrak </strong>if you notice any visible sign of deterioration.</p><p>-&nbsp; Medicines should<em> </em>not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Active ingredient is Lyophilized acyclovir sodium. &nbsp;Each vial contains Lyophilized acyclovir sodium equivalent to acyclovir 250mg.</p><p>Excipients: Sodium hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lovrak vials for I.V. infusion is available in pack of 1 vial and 10 vials.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                3/12/2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي<strong> لفراك</strong> على دواء يعرف باسم أسيكلوفير. والذي&nbsp; ينتمي إلى مجموعة من الأدوية تعرف باسم&nbsp; مضادات الفيروسات. وهو يعمل عن طريق القضاء أو وقف نمو الفيروسات.</p><p><strong>من الممكن أن يستخدم &nbsp;لفراك في </strong><strong>:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; &nbsp;علاج &nbsp;الجديري المائي</p><p>&bull;&nbsp;&nbsp;&nbsp; علاج الحالات الحادة من الهربس التناسلي</p><p>&bull;&nbsp;&nbsp;&nbsp; علاج ووقف التقرحات الباردة والهربس التناسلي لدى الأشخاص الذين يعمل الجهاز المناعي لديهم بكفاءة أقل ، والذي يعني أنه ليس لأجسامهم القدرة على القضاء على العدوى.</p><p>&bull;&nbsp;&nbsp;&nbsp; علاج العدوى الفيروسية الخطيرة لدى الأطفال بعمر يصل إلى 3 أشهر. نادراً ما يمكن أن يكون ناجماً عن &nbsp;الفيروس المسؤول عن &nbsp;حدوث عدوى التقرحات &nbsp;الباردة والهربس التناسلي.</p><p>&bull;&nbsp;&nbsp;&nbsp; علاج التهاب الدماغ. نادرا ما يمكن أن يكون ناجماً عن الفيروس المسؤول عن عدوى التقرحات الباردة والهربس التناسلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يجب عدم إعطائك لفراك في الحالات التالية:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية&nbsp; تجاه أسيكلوفير أو فالاسيكلوفير أو أي من المكونات الأخرى من هذا الدواء (المذكورة في بند 6(</p><p>يجب عدم استعمال <strong>لفراك</strong> إذا كان ما ذكر أعلاه &nbsp;ينطبق عليك. يرجى منك التحدث إلى طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل استعمال <strong>لفراك</strong>.</p><p><strong>تحذيرات واحتياطات</strong></p><p>يرجى منك التحدث إلى طبيبك &nbsp;المعالج أو الصيدلي الذي تتعامل معه قبل استعمال <strong>لفراك</strong> إذا:</p><p>&bull;&nbsp;&nbsp;&nbsp; كنت تعاني من مشاكل في الكلى</p><p>&bull;&nbsp;&nbsp;&nbsp; كنت بعمر أكبر من 65 عاماً</p><p>يرجى منك التحدث إلى طبيبك المعالج&nbsp; أو الصيدلي الذي تتعامل معه قبل استعمال <strong>لفراك</strong>، مالم تكن متأكداً من أياً مما ذكر أعلاه ينطبق عليك.</p><p>من الضروري شرب كمية كافية من الماء أثناء فترة استعمال <strong>لفراك.</strong></p><p><strong>تناول الأدوية الأخرى مع لفراك </strong></p><p>يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه، &nbsp;إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى. يتضمن ذلك الأدوية التي تصرف بدون وصفة طبية، بما في ذلك الأدوية العشبية.</p><p>وبصفة خاصة يرجى منك اخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تتناول أياً من الأدوية التالية:</p><p>&bull;&nbsp;&nbsp;&nbsp; بروبينسيد، ويستخدم لعلاج داء النقرس</p><p>&bull;&nbsp;&nbsp;&nbsp; سيميتيدين، ويستخدم لعلاج قرحات المعدة</p><p>&bull;&nbsp;&nbsp;&nbsp; تاكروليمس، سيكلوسبورين أو ميكوفينولات موفيتيل، تستخدم &nbsp;لمنع رفض الجسم للأعضاء المزروعة.</p><p><strong>الحمل، الرضاعة الطبيعية والخصوبة</strong></p><p>يرجى منك استشارة طبيبك المعالج، الصيدلي الذي تتعاملين معه، لطلب النصيحة قبل استعمال <strong>لفراك</strong>، إذا كنت حاملاً ترضعين طفلك رضاعة طبيعية، تعتقدين أنك قد تكونين حاملاً أو تخططين لإنجاب طفل.</p><p><strong>معلومات هامة حول بعض مكونات لفراك</strong></p><p>يحتوي <strong>لفراك </strong>على الصوديوم، يجب أن يؤخذ بعين الاعتبار من قبل المرضى الذين يتبعون نظاماً غذائياً متوازن في نسبة الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف يتم إعطاء الدواء الخاص بك:</strong></p><p>ليس من المتوقع أبداً أن تأخذ هذا الدواء من تلقاء نفسك. &nbsp;فسوف يكون هناك دائماً شخصاً مؤهلاً لإعطائك الدواء الخاص بك. &nbsp;</p><p>سوف يتم تخفيف الدواء قبل إعطائه لك.</p><p>سوف يتم إعطائك <strong>لفراك</strong> عن طريق التسريب الوريدي المستمر. لذلك يعطى الدواء لك ببطء على مدى فترة زمنية طويلة.</p><p>سوف تعتمد الجرعة المعطاة، &nbsp;معدل تكرارها والمدة الزمنية لإعطاء الجرعة سوف على:</p><p>&bull;&nbsp;&nbsp;&nbsp; &nbsp;نوع العدوى التي تعاني منها.</p><p>&bull;&nbsp;&nbsp;&nbsp; الوزن</p><p>&bull;&nbsp;&nbsp;&nbsp; العمر.</p><p><strong>سوف يقوم طبيبك المعالج بتعديل الجرعة الخاصة بك من لفراك إذا:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; كنت تعاني من مشاكل في الكلى. إذا كنت تعاني من مشاكل في الكلى، فمن الضروري أن تشرب الكثير من السوائل خلال فترة العلاج مع دواء <strong>لفراك.</strong> &nbsp;</p><p>&nbsp;&nbsp;&nbsp; يرجى منك التحدث إلى طبيبك المعالج قبل استعمال<strong> لفراك</strong> إذا أياً مما ذكر أعلاه ينطبق عليك.</p><p><strong>إذا تم إعطائك لفراك بجرعة أكبر مما يجب</strong></p><p>يرجى منك التحدث إلى طببيك المعالج أو الممرضة على الفور، إذا كنت تعتقد أنه تم إعطائك <strong>لفراك</strong> بجرعة أكبر مما يجب.</p><p>قد تعاني من الآتي، إذا تم إعطائك <strong>لفراك</strong> بجرعة أكبر مما يجب:</p><p>&bull;&nbsp;&nbsp;&nbsp; &nbsp;الشعور بالقلق أوالارتباك</p><p>&bull;&nbsp;&nbsp;&nbsp; الهلوسة (رؤية أو سماع أشياء غير موجودة(</p><p>&bull;&nbsp;&nbsp;&nbsp; تعاني من نوبات تشنجية</p><p>&nbsp;</p><p>&bull; &nbsp;فقدان الوعي (غيبوبة)</p><p><strong>إذا كان لديك أية أسئلة إضافية حول استعمال هذا الدواء، يرجى منك استشارة طببيك المعالج أو الصيدلي الذي تتعامل معه.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، قد يؤدي هذا الدواء إلى حدوث تأثيرات جانبية، ولكنها قد لا تحدث لكل شخص.</p><p>قد تحدث التأثيرات الجانبية التالية أثناء فترة استعمال هذا الدواء:</p><p><strong>التفاعلات التحسسية</strong> <strong>(قد يؤثر على ما يصل إلى &nbsp;شخص 1 من كل 10000 شخص</strong><strong>(</strong></p><p>إذا كنت تعاني من تفاعل تحسسي، <strong>فيرجى منك التوقف عن استعمال لفراك ويجب عليك</strong><strong> </strong><strong>مراجعة الطبيب المعالج على الفور.</strong> &nbsp;قد تتضمن علامات ذلك على:</p><p>&bull;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة أو طفح جلدي على شكل خلايا النحل</p><p>&bull;&nbsp;&nbsp;&nbsp; تورم&nbsp; الوجه، الشفتين، اللسان أو الأجزاء الأخرى من الجسم</p><p>&bull;&nbsp;&nbsp;&nbsp; ضيق في التنفس، ازيز أو مشاكل في التنفس</p><p>&bull;&nbsp;&nbsp;&nbsp; حمى غير مبررة (ارتفاع درجة حرارة الجسم)، والشعور بالإغماء، وبصفة خاصة عند الوقوف.</p><p><strong>تتضمن التأثيرات الجانبية الأخرى على</strong><strong>:</strong></p><p><strong>شائعة </strong>(قد يؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص(</p><p>&bull;&nbsp;&nbsp;&nbsp; الشعور بالإعياء أو التوعك</p><p>&bull;&nbsp;&nbsp;&nbsp; طفح جلدي شبيه بخلايا النحل مصحوباً بحكة</p><p>&bull;&nbsp;&nbsp;&nbsp; تفاعلات جلدية &nbsp;بعد التعرض للضوء (حساسية تجاه الضوء)</p><p>&bull;&nbsp;&nbsp;&nbsp; حكة</p><p>&bull;&nbsp;&nbsp;&nbsp; تورم واحمرار وألم في موضع الحقن عند اللمس.</p><p>&bull;&nbsp;&nbsp;&nbsp; ارتفاع في إنزيمات الكبد.</p><p><strong>غير شائعة</strong> (قد تؤثر على ما يصل إلى شخص واحد&nbsp; من كل 100 شخص(</p><p>&bull;&nbsp;&nbsp;&nbsp; انخفاض تعداد &nbsp;خلايا الدم الحمراء ( فقر الدم(</p><p>&bull;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم البيضاء (قلة العدلات)</p><p>&bull;&nbsp;&nbsp;&nbsp; قلة تعداد الصفائح الدموية (الخلايا التي تساعد على تجلط الدم) ( قلة الصفيحات(</p><p><strong>نادرة جدا</strong> (قد يؤثر على ما يصل إلى شخص واحد من كل &nbsp;10000 شخص(</p><p>&bull;&nbsp;&nbsp;&nbsp; الصداع أو الشعور بالدوار</p><p>&bull;&nbsp;&nbsp;&nbsp; إسهال أو آلام في المعدة</p><p>&bull;&nbsp;&nbsp;&nbsp; الشعور &nbsp;بالتعب</p><p>&bull;&nbsp;&nbsp;&nbsp; حمى</p><p>&bull;&nbsp;&nbsp;&nbsp; التأثيرات على بعض فحوصات البول والدم</p><p>&bull;&nbsp;&nbsp;&nbsp; الشعور بالضعف</p><p>&bull;&nbsp;&nbsp;&nbsp; الشعور بالقلق والارتباك</p><p>&bull;&nbsp;&nbsp;&nbsp; الارتعاش والتأرجح</p><p>&bull;&nbsp;&nbsp;&nbsp; الهلوسة (رؤية أو سماع أشياء غير موجودة(</p><p>&bull;&nbsp;&nbsp;&nbsp; نوبات تشنجية</p><p>&bull;&nbsp;&nbsp;&nbsp; الشعورالغير عادي بالنوم&nbsp; أو النعاس</p><p>&bull;&nbsp;&nbsp;&nbsp; عدم الثبات عند المشي وعدم التناسق في الحركة</p><p>&bull;&nbsp;&nbsp;&nbsp; صعوبة في الكلام</p><p>&bull;&nbsp;&nbsp;&nbsp; عدم القدرة على التفكير بشكل واضح أو الحكم على الأشياء</p><p>&bull;&nbsp;&nbsp;&nbsp; فقدان الوعي (الغيبوبة(</p><p>&bull;&nbsp;&nbsp;&nbsp; شلل في جزء أو كل اجزاء الجسم</p><p>&bull;&nbsp;&nbsp;&nbsp; اضطرابات في السلوك والكلام وحركات العين</p><p>&bull;&nbsp;&nbsp;&nbsp; تصلب الرقبة والحساسية للضوء</p><p>&bull;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p>&bull;&nbsp;&nbsp;&nbsp; اصفرار الجلد وبياض العينين (اليرقان(</p><p>&bull;&nbsp;&nbsp;&nbsp; مشاكل في الكلى التي تؤدي إلى قلة التبول أو عدم التبول</p><p>&bull;&nbsp;&nbsp;&nbsp; ألم في أسفل الظهر، ومنطقة الكلى من الظهر أو فقط فوق الورك (ألم الكلى)</p><p><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية:</u></strong><br /><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p><strong>رقم الفاكس:&nbsp;&nbsp; 7662-205-11-966+</strong></p><p><strong>يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على: 2038222-11-966+&nbsp; </strong></p><p><strong>وصلة هاتف:2340-2334-2354-2353-2356-2317</strong></p><p><strong>الهاتف المجاني: 8002490000</strong></p><p><strong>البريد الإلكتروني:</strong><strong> </strong><strong>&nbsp;</strong><strong>npc.drug@sfda.gov.sa</strong></p><p><strong>الموقع الإلكتروني: www.sfda.gov.sa/npc</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;&nbsp;&nbsp; يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p>-&nbsp;&nbsp;&nbsp; يجب عدم استعمال <strong>لفراك</strong> بعد تاريخ انتهاء الصلاحية المذكور على العبوة والملصق الداخلي.</p><p>-&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30&ordm;م.</p><p>-&nbsp;&nbsp;&nbsp; يجب عدم استعمال <strong>لفراك</strong> إذا لاحظت وجود&nbsp; أي علامات تلف واضحة.</p><p>-&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية عبر المياة المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي أسيكلوفير. تحتوي كل زجاجة على أسيكلوفير الصوديوم (مجفف بالتجميد) بما يعادل</p><p>&nbsp;250 ملغم من أسيكلوفير</p><p>المواد غير الفعالة: &nbsp;هيدروكسيد الصوديوم وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            تتوفر زجاجات لفراك للتسريب في الوريد  في عبوة تحتوي على زجاجة واحدة و10 زجاجات.


        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            3/12/2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lovrak 250mg Powder for I.V. Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains:
Item No.	Material Name 	Scale (mg/Vial)
		
	Inactive Ingredient:	
1.		Acyclovir sodium 	275.000
	Equivalent to Acyclovir	250.000
		
	Inactive Ingredients:	
1.		Sodium hydroxide pellets 	q.s. 
2.		Water for injection	q.s.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for I.V. Infusion
Description: White or almost white lyophilized powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; <strong>Lovrak</strong> is indicated for the treatment of&nbsp;<em>Herpes simplex</em>&nbsp;infections in immuno- compromised patients and severe initial genital herpes in the non-immuno compromised.</p><p>&sect; <strong>Lovrak </strong>is indicated for the prophylaxis of&nbsp;<em>Herpes simplex</em>&nbsp;infections in immuno-compromised patients.</p><p>&sect; <strong>Lovrak </strong>is indicated for the treatment of&nbsp;<em>Varicella zoster</em>&nbsp;infections.</p><p>&sect; <strong>Lovrak </strong>is indicated for the treatment of herpes encephalitis.</p><p>&sect; <strong>Lovrak </strong>is indicated for the treatment of&nbsp;<em>Herpes simplex&nbsp;</em>infections in the neonate and infant up to 3 months of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Route of administration:</u></strong>&nbsp;</p><p>Slow intravenous infusion over 1 hour.</p><p>A course of treatment with <strong>Lovrak</strong> usually lasts 5 days, but this may be adjusted according to the patient&#39;s condition and response to therapy. Treatment for herpes encephalitis usually lasts 10 days. Treatment for neonatal herpes infections usually lasts 14 days for mucocutaneous (skin-eye-mouth) infections and 21 days for disseminated or central nervous system disease.</p><p>The duration of prophylactic administration of <strong>Lovrak </strong>is determined by the duration of the period at risk.</p><p><strong><u>Dosage in adults:</u></strong></p><p>Patients with&nbsp;<em>Herpes simplex</em>&nbsp;(except herpes encephalitis) or&nbsp;<em>Varicella zoster&nbsp;</em>infections should be given Acyclovir in doses of 5 mg/kg body weight every 8 hours provided renal function is not impaired (see Dosage in renal impairment).</p><p>Immunocompromised patients with&nbsp;<em>Varicella zoster</em>&nbsp;infections or patients with herpes encephalitis should be given Acyclovir in doses of 10 mg/kg body weight every 8 hours provided renal function is not impaired (see Dosage in renal impairment).</p><p>In obese patients dosed with intravenous acyclovir based on their actual body weight, higher plasma concentrations may be obtained (see 5.2 Pharmacokinetic properties). Consideration should therefore be given to dosage reduction in obese patients and especially in those with renal impairment or the elderly.</p><p><strong><u>Dosage in infants and children:</u></strong>&nbsp;</p><p>The dose of Acyclovir for infants and children aged between 3 months and 12 years is calculated on the basis of body surface area.</p><p>Infants and children 3 months of age or older with<em>&nbsp;Herpes simplex</em>&nbsp;(except herpes encephalitis) or&nbsp;<em>Varicella zoster </em>infections should be given Acyclovir in doses of 250 mg per square metre of body surface area every 8 hours if renal function is not impaired.</p><p>In immunocompromised children with&nbsp;<em>Varicella zoster</em>&nbsp;infections or children with herpes encephalitis, Acyclovir should be given in doses of 500 mg per square metre body surface area every 8 hours if renal function is not impaired.</p><p>The dosage of Acyclovir in neonates and infants up to 3 months of age is calculated on the basis of body weight.</p><p>The recommended regimen for infants treated for known or suspected neonatal herpes is acyclovir 20 mg/kg body weight IV every 8 hours for 21 days for disseminated and CNS disease, or for 14 days for disease limited to the skin and mucous membranes.</p><p>Infants and children with impaired renal function require an appropriately modified dose; according to the degree of impairment (see Dosage in renal impairment).</p><p><strong><u>Dosage in the elderly:</u></strong></p><p>The possibility of renal impairment in the elderly must be considered and dosage should be adjusted accordingly (see <em>Dosage in renal impairment</em>&nbsp;below).</p><p>Adequate hydration should be maintained.</p><p><strong><u>Dosage in renal impairment:</u></strong></p><p>Caution is advised when administering Acyclovir to patients with impaired renal function. Adequate hydration should be maintained.</p><p>Dosage adjustment for patients with renal impairment is based on creatinine clearance, in units of ml/min for adults and adolescents and in units of ml/min/1.73m<sup>2</sup>&nbsp;for infants and children less than 13 years of age. The following adjustments in dosage are suggested:</p><p><strong>Dosage adjustments in adults and adolescents:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Creatinine Clearance</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Dosage</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>25 to 50 ml/min</p></td><td style="vertical-align:top"><p>The dose recommended above (5 or 10 mg/kg body weight) should be given every 12 hours.</p></td></tr><tr><td style="vertical-align:top"><p>10 to 25 ml/min</p></td><td style="vertical-align:top"><p>The dose recommended above (5 or 10 mg/kg body weight) should be given every 24 hours.</p></td></tr><tr><td style="vertical-align:top"><p>0(anuric) to 10 ml/min</p></td><td style="vertical-align:top"><p>In patients receiving continuous ambulatory peritoneal dialysis (CAPD) the dose recommended above (5 or 10 mg/kg body weight) should be halved and administered every 24 hours.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>In patients receiving haemodialysis the dose recommended above (5 or 10 mg/kg body weight) should be halved and administered every 24 hours and after dialysis.</p></td></tr></tbody></table><p><strong>Dosage adjustments in infants and children:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Creatinine Clearance</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Dosage</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>25 to 50 ml/min/1.73m2</p></td><td style="vertical-align:top"><p>The dose recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be given every 12 hours.</p></td></tr><tr><td style="vertical-align:top"><p>10 to 25 ml/min/1.73m2</p></td><td style="vertical-align:top"><p>The dose recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be given every 24 hours.</p></td></tr><tr><td style="vertical-align:top"><p>0(anuric) to 10 ml/min/1.73m2</p></td><td style="vertical-align:top"><p>In patients receiving continuous ambulatory peritoneal dialysis (CAPD) the dose recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be halved and administered every 24 hours.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>In patients receiving haemodialysis the dose recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be halved and administered every 24 hours and after dialysis</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to acyclovir or valacyclovir or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adequate hydration should be maintained in patients given i.v. or high oral doses of acyclovir.</p><p>Intravenous doses should be given by infusion over one hour to avoid precipitation of acyclovir in the kidney; rapid or bolus injection should be avoided.</p><p>The risk of renal impairment is increased by use with other nephrotoxic drugs. Care is required if administering i.v. acyclovir with other nephrotoxic drugs.</p><p><strong><u>Use in patients with renal impairment and in elderly patients:</u></strong></p><p>Acyclovir is eliminated by renal clearance, therefore the dose must be adjusted in patients with renal impairment (see section 4.2 Posology and method of administration). Elderly patients are likely to have reduced renal function and therefore the need for dose adjustment must be considered in this group of patients. Both elderly patients and patients with renal impairment are at increased risk of developing neurological side effects and should be closely monitored for evidence of these effects. In the reported cases, these reactions were generally reversible on discontinuation of treatment (see section 4.8 Undesirable effects). Prolonged or repeated courses of acyclovir in severely immune-compromised individuals may result in the selection of virus strains with reduced sensitivity, which may not respond to continued acyclovir treatment (see section 5.1).</p><p>In patients receiving acyclovir at higher doses (e.g. for herpes encephalitis) specific care regarding renal function should be taken, particularly when patients are dehydrated or have any renal impairment.</p><p>Reconstituted acyclovir has a pH of approximately 11 and should not be administered by mouth. Product contains sodium. To be taken into consideration by patients on a controlled sodium diet.</p><p>Acyclovir contains no antimicrobial preservative. Reconstitution and dilution should therefore be carried out under full aseptic conditions immediately before use and any unused solution discarded. The reconstituted or diluted solutions should not be refrigerated.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acyclovir is eliminated primarily unchanged in the urine via active renal tubular secretion. Any drugs administered concurrently that compete with this mechanism may increase acyclovir plasma concentrations. Probenecid and cimetidine increase the AUC of acyclovir by this mechanism and reduce acyclovir renal clearance. However no dosage adjustment is necessary because of the wide therapeutic index of acyclovir.</p><p>In patients receiving intravenous acyclovir caution is required during concurrent administration with drugs which compete with acyclovir for elimination, because of the potential for increased plasma levels of one or both drugs or their metabolites. Increases in plasma AUCs of acyclovir and of the inactive metabolite of mycophenolate mofetil, an immunosuppressant agent used in transplant patients, have been shown when the drugs are co-administered.</p><p>If&nbsp;<strong>lithium&nbsp;</strong>is administered concurrently with high dose acyclovir IV, the lithium serum concentration should be closely monitored because of the risk of lithium toxicity.</p><p>Care is also required (with monitoring for changes in renal function) if administering intravenous acyclovir with drugs which affect other aspects of renal physiology (e.g. cyclosporin, tacrolimus).</p><p>An experimental study on five male subjects indicates that concomitant therapy with acyclovir increases AUC of totally administered&nbsp;<strong>theophylline</strong>&nbsp;with approximately 50%. It is recommended to measure plasma concentrations during concomitant therapy with acyclovir.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Fertility:</u></strong></p><p>There is no information on the effect of acyclovir on human female fertility.</p><p>In a study of 20 male patients with normal sperm count, oral acyclovir administered at doses of up to 1g per day for up to six months has been shown to have no clinically significant effect on sperm count, motility or morphology.</p><p>See clinical studies in section 5.2</p><p><strong><u>Pregnancy:</u></strong></p><p>A post-marketing acyclovir pregnancy registry has documented pregnancy outcomes in women exposed to any formulation of acyclovir. The registry findings have not shown an increase in the number of birth defects amongst acyclovir exposed subjects compared to with the general population, and any birth defects showed no uniqueness or consistent pattern to suggest a common cause. Systemic administration of acyclovir in internationally accepted standard tests did not produce embryotoxic or teratogenic effects in rabbits, rats or mice. In a non-standard test in rats, foetal abnormalities were observed but only following such high subcutaneous doses that maternal toxicity was produced. The clinical relevance of these findings is uncertain.</p><p>Caution should therefore be exercised by balancing the potential benefits of treatment against any possible hazard. Findings from reproduction toxicology studies are included in Section 5.3.</p><p><strong><u>Breast-feeding:</u></strong></p><p>Following oral administration of 200 mg five times a day, acyclovir has been detected in human breast milk at concentrations ranging from 0.6 to 4.1 times the corresponding plasma levels. These levels would potentially expose nursing infants to acyclovir dosages of up to 0.3 mg/kg body weight/day. Caution is therefore advised if acyclovir is to be administered to a nursing woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acyclovir I.V. for infusion is generally used in an in-patient hospital population and information on ability to drive and operate machinery is not usually relevant. There have been no studies to investigate the effect of acyclovir on driving performance or the ability to operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The frequency categories associated with the adverse events below are estimates. For most events, suitable data for estimating incidence were not available. In addition, adverse events may vary in their incidence depending on the indication.</p><p>The following convention has been used for the classification of undesirable effects in terms of frequency: Very common &ge; 1/10, common &ge; 1/100 and &lt; 1/10, uncommon &ge; 1/1,000 and &lt; 1/100, rare &ge; 1/10,000 and &lt; 1/1,000, very rare &lt; 1/10,000.</p><p><strong><u>Blood and lymphatic system disorders:</u></strong></p><p>Uncommon: decreases in haematological indices (anaemia, thrombocytopenia, and leukopenia).</p><p><strong><u>Immune system disorders:</u></strong></p><p>Very rare: anaphylaxis.</p><p><strong><u>Psychiatric and nervous system disorders:</u></strong></p><p>Very rare: headache, dizziness, agitation, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, convulsions, somnolence, encephalopathy, and coma.</p><p>The above events are generally reversible and usually reported in patients with renal impairment or with other predisposing factors (see 4.4 Special Warnings and Precautions for Use).</p><p><strong><u>Vascular disorders:</u></strong></p><p>Common: phlebitis.</p><p><strong><u>Respiratory, thoracic and mediastinal disorders:</u></strong></p><p>Very rare: dyspnoea.</p><p><strong><u>Gastrointestinal disorders:</u></strong></p><p>Common: nausea, vomiting.</p><p>Very rare: diarrhoea, abdominal pain.</p><p><strong><u>Hepato-biliary disorders:</u></strong></p><p>Common: reversible increases in liver-related enzymes.</p><p>Very rare: reversible increases in bilirubin, jaundice, hepatitis.</p><p><strong><u>Skin and subcutaneous tissue disorders:</u></strong></p><p>Common: pruritus, urticaria, rashes (including photosensitivity).</p><p>Very rare: angioedema.</p><p><strong><u>Renal and urinary disorders:</u></strong></p><p>Common: increases in blood urea and creatinine.</p><p>Rapid increases in blood urea and creatinine levels are believed to be related to the peak plasma levels and the state of hydration of the patient. To avoid this effect the drug should not be given as an intravenous bolus injection but by slow infusion over a one-hour period.</p><p>Very rare: renal impairment, acute renal failure and renal pain.</p><p>Adequate hydration should be maintained. Renal impairment usually responds rapidly to rehydration of the patient and/or dosage reduction or withdrawal of the drug. Progression to acute renal failure however, can occur in exceptional cases.</p><p>Renal pain may be associated with renal failure and crystalluria.</p><p><strong><u>General disorders and administration site conditions:</u></strong></p><p>Very rare: fatigue, fever, local inflammatory reactions</p><p>Severe local inflammatory reactions sometimes leading to breakdown of the skin have occurred when acyclovir has been inadvertently infused into extracellular tissues.</p><p><strong><u>To report any side effect(s):</u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222, <strong>Exts:</strong> 2317-2356-2353-2354-2334-2340.</p><p><strong>Toll free phone:</strong> 8002490000</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdosage of intravenous acyclovir has resulted in elevations of serum creatinine, blood urea nitrogen and subsequent renal failure. Neurological effects including confusion, hallucinations, agitation, seizures and coma have been described in association with overdosage.</p><p>Patients should be observed closely for signs of toxicity. Haemodialysis significantly enhances the removal of acyclovir from the blood and may, therefore, be considered an option in the management of overdose of this drug.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Direct acting antivirals, Nucleosides and nucleotides excl. reverse transcriptase inhibitors</p><p><strong>ATC code:</strong> J05AB01.</p><p>Acyclovir is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against human herpes viruses, including Herpes simplex virus types 1 and 2 and Varicella zoster virus (VZV), Epstein Barr virus (EBV) and Cytomegalovirus (CMV). In cell culture acyclovir has the greatest antiviral activity against HSV-1, followed (in decreasing order of potency) by HSV-2, VZV, EBV and CMV.</p><p>The inhibitory activity of acyclovir for HSV-1, HSV-2, VZV and EBV is highly selective. The enzyme thymidine kinase (TK) of normal, uninfected cells does not use acyclovir effectively as a substrate, hence toxicity to mammalian host cells is low; however, TK encoded by HSV, VZV and EBV converts acyclovir to acyclovir monophosphate, a nucleoside analogue, which is further converted to the diphosphate and finally to the triphosphate by cellular enzymes. Acyclovir triphosphate interferes with the viral DNA polymerase and inhibits viral DNA replication with resultant chain termination following its incorporation into the viral DNA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In adults, the terminal plasma half-life of acyclovir after administration of acyclovir I.V. is about 2.9 hours. Most of the drug is excreted unchanged by the kidney. Renal clearance of acyclovir is substantially greater than creatinine clearance, indicating that tubular secretion, in addition to glomerular filtration, contributes to the renal elimination of the drug. 9-carboxymethoxy-methylguanine is the only significant metabolite of acyclovir and accounts for 10 to 15% of the dose excreted in the urine.</p><p>When acyclovir is given one hour after 1 gram of probenecid, the terminal half-life and the area under the plasma concentration time curve are extended by 18% and 40% respectively.</p><p>In adults, mean steady state peak plasma concentrations (C<sup>ss</sup>max) following a one-hour infusion of 2.5 mg/kg, 5 mg/kg and 10 mg/kg were 22.7 micromolar (5.1 microgram/ml), 43.6 micromolar (9.8 microgram/ml) and 92 micromolar (20.7 microgram/ml) respectively. The corresponding trough levels (C<sup>ss</sup>min) 7 hours later were 2.2 micromolar (0.5 microgram/ml), 3.1 micromolar (0.7 microgram/ml) and 10.2 micromolar (2.3 microgram/ml) respectively. In children over 1 year of age similar mean peak (C<sup>ss</sup>max) and trough (C<sup>ss</sup>min) levels were observed when a dose of 250 mg/m<sup>2</sup>&nbsp;was substituted for 5 mg/kg and a dose of 500 mg/m<sup>2</sup>&nbsp;was substituted for 10 mg/kg. In neonates (0 to 3 months of age) treated with doses of 10 mg/kg administered by infusion over a one-hour period every 8 hours the C<sup>ss</sup>max was found to be 61.2 micromolar (13.8 microgram/ml) and the C<sup>ss</sup>min to be 10.1 micromolar (2.3 microgram/ml). A separate group of neonates treated with 15 mg/kg every 8 hours showed approximate dose proportional increases, with a Cmax of 83.5 micromolar (18.8 microgram/ml) and Cmin of 14.1 micromolar (3.2 microgram/ml).</p><p>The terminal plasma half-life in these patients was 3.8 hours. In the elderly, total body clearance falls with increasing age and is associated with decreases in creatinine clearance although there is little change in the terminal plasma half-life.</p><p>In patients with chronic renal failure the mean terminal half-life was found to be 19.5 hours. The mean acyclovir half-life during haemodialysis was 5.7 hours. Plasma acyclovir levels dropped approximately 60% during dialysis.</p><p>In a clinical study in which morbidly obese female patients (n=7) were dosed with intravenous acyclovir based on their actual body weight, plasma concentrations were found to be approximately twice that of normal weight patients (n=5), consistent with the difference in body weight between the two groups.</p><p>Cerebrospinal fluid levels are approximately 50% of corresponding plasma levels.</p><p>Plasma protein binding is relatively low (9 to 33%) and drug interactions involving binding site displacement are not anticipated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Mutagenicity</u></strong><strong>:</strong></p><p>The results of a wide range of mutagenicity tests<em>&nbsp;in vitro&nbsp;</em>and<em>&nbsp;in vivo</em>&nbsp;indicate that acyclovir is unlikely to pose a genetic risk to man.</p><p><strong><u>Carcinogenicity</u></strong><strong>:</strong></p><p>Acyclovir was not found to be carcinogenic in long-term studies in the rat and the mouse.</p><p><strong><u>Teratogenicity</u></strong><strong>:</strong></p><p>Systemic administration of acyclovir in internationally accepted standard tests did not produce embryotoxic or teratogenic effects in rabbits, rats or mice</p><p>In a non-standard test in rats, foetal abnormalities were observed but only following such high subcutaneous doses that maternal toxicity was produced. The clinical relevance of these findings is uncertain.</p><p><strong><u>Fertility</u></strong><strong>:</strong></p><p>Largely reversible adverse effects on spermatogenesis in association with overall toxicity in rats and dogs have been reported only at doses of acyclovir greatly in excess of those employed therapeutically. Two-generation studies in mice did not reveal any effect of (orally administered) acyclovir on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:632px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top"><ol><li>Sodium hydroxide pellets</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Water for injection</li></ol></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lyophilized powder in a clear glass vial provided with a rubber stopper and flip-off aluminium seal, 1 vial packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Reconstitution: </u></strong></p><p><strong>Lovrak</strong> I.V. should be reconstituted using the following volumes of either Water for Injections BP or Sodium Chloride Intravenous Injection BP (0.9% w/v) to provide a solution containing 25mg acyclovir per mL:</p><table border="0" cellspacing="0" cellpadding="0" style="width:588px"><tbody><tr><td style="vertical-align:top"><p><strong>Formulation</strong></p></td><td style="vertical-align:top"><p><strong>Volume of fluid for reconstitution</strong></p></td></tr><tr><td style="vertical-align:top"><p>250mg vial</p></td><td style="vertical-align:top"><p>10 mL</p></td></tr></tbody></table><p>From the calculated dose, determine the appropriate number and strength of vials to be used. To reconstitute each vial add the recommended volume of infusion fluid and shake gently until the contents of the vial have dissolved completely.</p><p><strong>The reconstituted solution is stable for up to 12 hours at room temperature.</strong></p><p><strong><u>Administration:</u></strong></p><p>The required dose of acyclovir I.V. should be administered by slow intravenous infusion over a one-hour period.</p><p>After reconstitution acyclovir I.V. may be administered by a controlled-rate infusion pump.</p><p>Alternatively, the reconstituted solution may be further diluted to give an acyclovir concentration of not greater than 5 mg/ml (0.5% w/v) for administration by infusion:</p><p>Add the required volume of reconstituted solution to the chosen infusion solution, and shake well to ensure adequate mixing occurs.</p><p>For children and neonates, where it is advisable to keep the volume of infusion fluid to a minimum, it is recommended that dilution is on the basis of 4mL reconstituted solution (100 mg acyclovir) added to 20mL of infusion fluid.</p><p>For adults, it is recommended that infusion bags containing 100mL of infusion fluid are used, even when this would give an acyclovir concentration substantially below 0.5% w/v. Thus one 100mL infusion bag may be used for any dose between 250 mg and 500 mg acyclovir (10 and 20 ml of reconstituted solution) but a second bag must be used for doses between 500 mg and 1000 mg.</p><p>Since no antimicrobial preservative is included, reconstitution and dilution must be carried out under full aseptic conditions, immediately before use, and any unused solution discarded.</p><p>Should any visible turbidity or crystallisation appear in the solution before or during infusion, the preparation should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street.
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06. February. 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>